It is an exciting time for the field of antibody-drug conjugates (ADCs), and today’s media has no shortage of writing about the direction this modality is taking: novel platforms, next‑generation payloads, and high‑profile acquisitions are all driving headlines about its future potential.
However, what is equally compelling about the ADC story is how ADCs were able to shift from a high‑risk, niche treatment to a robust therapeutic class. Drawing on The Tipping Point by Malcolm Gladwell, this article steps back from the current excitement to examine a simple question: what specific turning point finally allowed ADCs to grow?
As suggested by the tagline of The Tipping Point, minor, frequently overlooked events can cause much larger shifts in momentum. In Gladwell’s examples, from Sesame Street to the unexpected resurgence of ‘Hush Puppies’, these turning points were driven by the amplifying impact of social connectors.1 It can be argued that much of the recent success of ADCs can also be traced back to connectors.
Early antibody‑drug conjugate development and first‑generation challenges
ADC clinical development has been ongoing for several decades, with first-in-human trials dating back to the 1980s.8 Even so, the ADC market remained in its infancy for many years.
In 2000, the first ADC to receive FDA approval was the first-generation Mylotarg (gemtuzumab ozogamicin), a CD33-targeting ADC approved for CD33-positive acute myeloid leukemia in older patients with limited treatment options.9,11
Although expectations were high for this first-generation “magic bullet,” the accelerated approval was premature. Even though early research seemed promising, confirmatory studies failed to demonstrate an advantage over standard therapy at the chosen dosing regimen while also reporting higher treatment-related mortality.
Mylotarg was subsequently voluntarily withdrawn from the market but reintroduced in 2017 for a broader indication and under a revised fractionated dosing regimen.11
Since CD33 is also expressed on healthy cells, its selection as a target contributed to toxicity, as is the case with many CD33-targeting drugs. However, the more fundamental issue was structural.
Mylotarg couples a cytotoxic payload to a CD33-targeting IgG4 antibody through an acid-cleavable linker. The conjugate was designed to remain intact in circulation and release the payload only after cellular internalization and lysosomal processing.
In practice, the first-generation construct lacked adequate plasma stability, while its high, heterogeneous payload and aggressive dosing schedule drove off-target exposure, contributing significantly to the drug’s toxicity profile.3
Mylotarg’s clinical setbacks epitomized the obstacles facing ADCs at the time and contributed to a period of caution around the field, as ADCs came to be seen as technically challenging, high-risk drugs.
Second‑generation antibody‑drug conjugates and linker innovation
Despite these challenges, a small number of companies, including Seagen and ImmunoGen, continued to develop next-generation payloads, improve conjugation approaches and linker chemistry, and construct proprietary platforms that set the stage for enhanced ADCs.
In 2011, the second generation of ADCs emerged with the arrival of Adcetris, the second FDA-approved ADC. The drug received approval for the treatment of relapsed/refractory Hodgkin’s lymphoma and anaplastic large cell lymphoma. This was followed by Kadcycla, an ADC for solid tumors, that would go on to become the first true commercial success within its class.
During Kadcyla’s development, multiple alternative cleavable linkers were assessed, alongside a non-cleavable version that served as a negative control. Unexpectedly, the non-cleavable construct not only exhibited superior plasma stability and a more favorable toxicity but also outperformed its cleavable counterparts in antitumor efficacy.
Kadcyla was later validated in metastatic and adjuvant HER2-positive breast cancer, helping establish ADCs as a credible class of therapeutics.3,6
Antibody‑drug conjugates enter solid tumors
Moving into solid tumors was equally substantial, given that most ADC targets up to that point had been in hematologic cancers, which, while clinically important, represent fewer than 10% of global cancer cases.12
Solid tumors also presented distinct obstacles, such as receptor saturation, tissue penetration, and the need to balance effectiveness with toxicity. The surprising success of Kadcyla, which ultimately became a standard of care, helped disprove earlier assumptions about ADC design and renewed interest in the class as a whole.
This success laid the foundation for next-generation ADCs, including Padcev, Trodelvy, and most notably Enhertu, the trastuzumab-based successor to Kadcyla. By leveraging third-generation ADC design characteristics, specifically site-directed conjugation, more stable cleavable linkers, and higher drug-to-antibody ratios, Enhertu delivered an unusual combination of strong tolerability and potent antitumor activity.
ADC market growth and the modern tipping point
Between 2017 and 2024, the ADC market underwent rapid expansion, growing from approximately $1.6 billion to $13.6 billion at a 35.8% compound annual growth rate. Enhertu has established itself as the leading product in the class, with anticipated sales of about $14.3 billion by 2031.2
This growth reflects more than commercial momentum: the market’s swift expansion has been fueled by an increasing number of approvals, showing that ADCs have moved beyond a handful of outliers and into the mainstream of oncology treatment.
Why antibody‑drug conjugates reached a tipping point
ADC history is best understood as a field shaped by key discoveries rather than a smooth progression. Ultimately, a small change in design transformed this therapy, altering the trajectory of clinical success. In The Tipping Point, this is the moment when a minor factor tips the system, converting sluggish development into accelerated and lasting impact.
In isolation, the change itself may have seemed trivial, but its impact illustrated Gladwell’s “Power of Context”: a precise intervention introduced at exactly the right moment in a complex biological and translational ecosystem. After crossing that threshold, efficacy, implementation, and patient outcomes progressed with remarkable momentum.
Driven partly by the fortunate selection of a non-cleavable linker, its success reset expectations regarding toxicity, proving that ADCs could be both clinically meaningful and commercially viable.
The broader lesson can also be applied to novel therapeutics as a whole, showing that when innovation and timing align, a single well-placed adjustment can be sufficient to revolutionize the pharmaceutical landscape.
By combining in-depth biological expertise with robust in vivo models, Synexa’s ADC solutions support informed decision‑making throughout discovery and development. The company generates high-quality data from target validation to translational pharmacology, enabling researchers to evaluate effectiveness, safety, and differentiation in an increasingly competitive ADC landscape.
References and further reading:
- Gladwell, M. (2000). The tipping point: How little things can make a big difference. Little, Brown and Company.
- (2026). Comprehensive Review of Historical, Current, and Emerging Antibody-Drug Conjugate Therapies (Report Code GDHCHT661). GlobalData.
- Joubert, N., et al. (2020). Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals (Basel, Switzerland), 13(9). DOI: 10.3390/ph13090245. https://www.mdpi.com/1424-8247/13/9/245.
- Krop, I. (2025). The Evolution of Antibody-Drug Conjugates in Oncology: Have we found our “Magic Bullet”? | Dr. Krop., Yale Cancer Center. Available at: https://youtu.be/zAEV8gtw318?si=aWhMeEr7L-d8gAKP.
- Lewis Phillips, G.D., et al. (2008). Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer research, 68(22), pp.9280–90. DOI: 10.1158/0008-5472.CAN-08-1776. https://aacrjournals.org/cancerres/article/68/22/9280/542757/Targeting-HER2-Positive-Breast-Cancer-with?guestAccessKey=.
- Lewis Phillips, G. (2020). Part 11 - Evolution of Antibody Drug conjugates in cancer - Dr. Gail Phillips, USA. h. MICE IDEAS Pvt. Ltd. Available at: https://youtu.be/scMMHcJ9xx0?si=Kq_ti05qzJYbi3gc.
- Peddi, P.F. and Hurvitz, S.A. (2014). Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 6(5), pp.202–209. DOI: 10.1177/1758834014539183. https://journals.sagepub.com/doi/10.1177/1758834014539183.
- Pettinato, M.C. (2021). Introduction to Antibody-Drug Conjugates. Antibodies, 10(4), p.42. DOI: 10.3390/antib10040042. https://www.mdpi.com/2073-4468/10/4/42.
- (2025). Recent Advances in Antibody-Drug Conjugates. NJ Bio, Inc. (December 2025).
- Rubahamya, B., Dong, S. and Thurber, G.M. (2024). Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Science Advances, 10(22). DOI: 10.1126/sciadv.adk1894. https://www.science.org/doi/10.1126/sciadv.adk1894.
- Selby, C., Yacko, L.R. and Glode, A.E. (2019). Gemtuzumab Ozogamicin: Back Again. Journal of the Advanced Practitioner in Oncology, 10(1), p.68. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6605703/. https://pmc.ncbi.nlm.nih.gov/articles/PMC6605703/.
- Tietsche de Moraes Hungria, V., et al. (2019). Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study. Journal of Global Oncology, (5), pp.1–19. DOI: 10.1200/jgo.19.00025. https://ascopubs.org/doi/10.1200/JGO.19.00025.
About Synexa Life Sciences
Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specializing in the development, validation, and delivery of a wide range of complex and custom-designed assays.
With a team of over 200 staff across three global laboratory locations: Manchester, Turku (Finland), and Cape Town, we provide innovative solutions to support our customers in achieving their clinical milestones.
Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilizing MSD, LC-MS/MS, ELISA, RIA, fluorescence, and luminescence-based technologies), cell biology (including flow cytometry, ELISpot, and Fluorospot), and genomic services to support clinical trials and translational studies.
We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.
Since 2019, Synexa has been backed by Gilde Healthcare, a specialized healthcare investor. Synexa, improving the quality of human health through innovative biomarker and bioanalytical solutions.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.